TILDRAKIZUMAB significantly improves both clinical disease severity and patient-reported quality of life outcomes in adults with moderate-to-severe chronic plaque psoriasis, according to a prospective real-world study.
Real-World Study Evaluates Tildrakizumab Over 52 Weeks
The study evaluated the impact of the interleukin (IL)-23p19 inhibitor over 52 weeks in a real-world clinical setting. While tildrakizumab has previously demonstrated strong efficacy and safety in clinical trials, evidence on its effects on patient-reported outcome measures (PROMs) outside trial settings has remained limited.
Chronic plaque psoriasis is associated with substantial physical discomfort and psychosocial burden, often affecting sleep, work productivity, emotional wellbeing, and social functioning. Increasingly, PROMs are being recognised as important endpoints alongside physician-assessed skin clearance.
The study enrolled 33 consecutive adults with moderate-to-severe plaque psoriasis who initiated treatment with tildrakizumab. Participants underwent assessments at baseline, week 16, and week 52 using the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), Skindex-16 questionnaire, visual analogue scales for pruritus, scaling, and pain, the Medical Outcomes Study Sleep Scale (MOS-Sleep), and the Work Productivity and Activity Impairment (WPAI) questionnaire.
Quality of Life and Psoriasis Symptoms Improved Significantly
Researchers reported rapid and sustained improvements in skin symptoms following treatment initiation. By week 16, patients experienced marked reductions in PASI scores alongside significant improvements in most PROMs, including itching, scaling, and dermatology-related quality of life. Improvements in pain and sleep disturbances became statistically significant later, at week 52.
The analysis also demonstrated strong early correlations between improvements in disease severity and patient-reported outcomes. At week 16, PASI improvements closely correlated with better DLQI scores and reduced pruritus. However, by week 52, these correlations weakened for several measures despite maintained skin clearance.
Findings Support Routine Use of PROMs in Psoriasis Care
According to the investigators, this pattern may reflect a process of patient adaptation once disease control is sustained over time, suggesting that improvements in quality of life become less directly tied to visible skin severity during long-term treatment.
The authors concluded that PROMs should remain an integral component of psoriasis management, as they capture broader patient-centred benefits that extend beyond objective skin clearance alone. The findings add to growing real-world evidence supporting the effectiveness of tildrakizumab in chronic plaque psoriasis.
Reference
Facheris P et al. Tildrakizumab improves disease severity and patient-reported outcomes in moderate-to-severe chronic plaque psoriasis: a prospective real-world study. Dermatol Ther (Heidelb). 2026; DOI: 10.1007/s13555-026-01760-8.
Featured image: Ольга Тернавская on Adobe Stock
